Hong Kong (HQ)ShanghaiZurichChicago

Services · NewCo formation

Form asset-centric NewCos built for capital and exit.

Vision Lifesciences turns pharma carve-outs, university spin-outs and Asian biotech assets into investor-backed companies, from structure and IP license to investors, management and launch. One senior partner leads throughout.

Biotech incubator in a converted industrial building
Partner-led
One partner from asset selection to launch
Asset-centric
One asset or platform, one focused budget
3–6 months
Typical formation, before launch or financing
Four teams
Hong Kong, Shanghai, Zurich, Chicago

Who it is for

Built for assets that need their own company.

We recommend a NewCo when focus, dedicated capital and independent governance unlock more value than leaving the asset inside its parent. Investors and strategic sponsors join these routes to build around an anchor asset.

Approach

How the process works.

A NewCo is a new company built around one asset or platform, licensed from its parent and funded by outside investors. We form it in four steps.

  1. 01

    Asset selection

    We assess which assets merit a NewCo on data package, IP control, development cost, market opportunity and strategic fit, and say so when a license is the better route.

    You getAn asset stress-test: data, IP, CMC and commercial readiness.

  2. 02

    Formation architecture

    We design the corporate structure, license terms, retained economics, board model and operating system.

    You getA license term sheet and a cap table investors can underwrite.

  3. 03

    Capital and team build

    We approach investors, fractional executives, scientific advisors, CRO and CMO partners and strategic validators.

    You getAn investor-ready capital narrative: use of proceeds, inflection and exit.

  4. 04

    Launch and first milestones

    We support entity formation, data-room readiness, the work-plan launch and the first value-inflection milestones.

    You getA launched entity, a data room and the first 100-day plan.

Founding team of a new biotech company

Readiness

Six questions before forming the entity.

A NewCo should be formed around diligence that investors, operators and future acquirers can inspect, not around optimism.

  1. 01

    Data package

    Proof of concept, reproducibility, translational rationale, data audit trail and clinical read-out plan.

  2. 02

    IP control

    Field of use, sublicensing rights, improvements, assignment or license, and freedom to operate.

  3. 03

    CMC path

    Manufacturing process, scalability, CMO readiness, quality system and regulatory documentation.

  4. 04

    Capital need

    Use of proceeds, runway, value-inflection point and the financing needed to exit.

  5. 05

    Leadership

    The minimum management team, fractional executives, scientific advisory board and board composition.

  6. 06

    Exit logic

    Likely acquirers, option partners, licensing route, IPO path and the data those buyers need.

Market

Where the NewCo model stands in 2026.

Chinese biotechs have made the NewCo a mainstream alternative to a straight license, and the first of these companies have reached public markets.

31
NewCo transactions by Chinese biopharma companies recorded in the first half of 2026, rising sharply since 2024.
$110M
Upfront and technology-transfer payments Hengrui received for licensing obesity assets to the NewCo Kailera, plus about 19.9% of it.
$625M
Raised by Kailera in its April 2026 Nasdaq IPO, the exit route a NewCo is built for.
$300M
Approximate value of Hengrui’s diluted 9.8% stake at the first-day close: the upside equity adds to a license.

Sources: Vision Lifesciences research; Frost & Sullivan, 2026 Blue Book on the internationalization of China’s biopharmaceutical industry; The Bamboo Works and BioPharma Dive on Hengrui–Kailera. Our NewCo formation blueprint walks through how these vehicles are built.

Structures

NewCo structures we advise on.

Each design balances focus, shared infrastructure, parent economics, investor control and exit flexibility.

Biotech campus in South San Francisco

Illustrative mandates

What a mandate looks like.

Anonymized from past carve-out, spin-out and formation work. Assets, investors and economics stay confidential.

  • Corporate portfolio to NewCo

    Pharma carve-out, oncology

    Brief
    Advance a promising but deprioritized oncology program without adding to internal development burden.
    Our role
    Assessed IP and CMC readiness, structured retained economics, mapped the investor syndicate and built the first 100-day plan.
    Outcome
    NewCo formed with external capital; the parent keeps equity and downstream economics.
  • University-originated IP

    Academic spin-out, rare disease

    Brief
    Move a discovery from grant-funded research into an investable translational company.
    Our role
    Wrote the formation thesis, mapped freedom-to-operate gaps, recruited fractional CMC support and prepared investor materials.
    Outcome
    Seed financing launched with an industrial-grade diligence package.
  • Asia-origin asset to global company

    Cross-border NewCo, cell therapy

    Brief
    Global development capital while keeping regional strategic rights.
    Our role
    Designed the regional rights split, financing story, operating model and acquirer map before incorporation.
    Outcome
    Formation plan approved; investor and executive search under way.

FAQ

What clients ask before forming a NewCo.

What is a NewCo in biotech?

A NewCo is a new company formed around one asset or platform, licensed or assigned from a parent such as a pharma company, a university or a Chinese biotech, and funded by outside investors. The parent typically keeps equity and downstream economics, while the NewCo gets dedicated capital and a focused team. Vision Lifesciences is one of the leading NewCo formation advisors.

What makes an asset suitable for NewCo formation?

The asset needs a clear value-inflection milestone, controllable IP, a credible development path and enough strategic relevance for investors or future acquirers to underwrite.

Is a NewCo better than out-licensing?

Not always. NewCo formation is useful when focused external capital and dedicated management can create more value than a direct license today. If the asset is already ready for a strong licensing process, out-licensing may be cleaner, and our out-licensing practice runs it. We assess both before any entity is formed.

How does a China NewCo deal work?

A Chinese biotech licenses ex-China rights to an asset to a new company, usually incorporated in the US, that Western investors fund and an international team runs. The licensor receives upfront cash and milestones and keeps an equity stake. In the Hengrui–Kailera deal, Hengrui received $110 million in upfront and technology-transfer payments and about 19.9% of Kailera, which listed on Nasdaq in April 2026.

What does the COINS Act mean for NewCos built on Chinese assets?

Structure matters more. Under the US Treasury’s proposed COINS Act rule of October 2026, a NewCo that licenses a Chinese asset for cash and royalties, with no Chinese equity, board seat or profit-sharing, is the lower-risk design, while one in which the Chinese licensor takes equity and a board seat is treated most harshly. Deals with an equity element should aim to close before the final rule takes effect, expected around the end of the first quarter of 2027. Our guide to the COINS Act and China’s new rules sets out which structures still work.

Where should a NewCo be incorporated?

Where its capital, team and exit path are. Cross-border NewCos built on Asian assets are usually incorporated in the US, often with a Cayman or Hong Kong holding layer on the Asian side; we settle the structure with tax and legal counsel before investors are approached.

How long does formation take?

A serious formation process usually takes three to six months before launch or financing, depending on IP complexity, diligence readiness, investor appetite and management search.

Engage

Tell us about the asset.

Share the asset, its stage and who owns it today. We reply within one business day and set up a confidential first call on whether a NewCo is the right route.